Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
FDA publishes shame list of firms fighting generic competitors
FDA shames companies accused of blocking generic drug development
Trump is right: Abusive patents are the culprit behind high drug prices, but his plan doesn’t solve anything
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents
Major Win for Patients as Brazil Rejects a Key Patent on Gilead Hepatitis C Drug and European Court of Justice Opinion Denies Patent Extension to Gilead’s HIV Drug
Tahir Amin: Increasing Access to Affordable HIV Drugs Through Patent Opposition
A Supreme Court victory for lowering drug prices
Tahir Amin: Transparency in Drug Pricing